Skip to content

Insider · CIK 0001742266

Daniel Barber

ceopresidentofficerdirector

Files at AQST (Aquestive Therapeutics, Inc.). First filing Sep 16, 2026, latest Sep 16, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $120k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

AQST: Aquestive Therapeutics, Inc.

AQSTOct 9, 2026 · close 4.78

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
23Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
$120k
25,000 shares
-4%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 15, 2026AQST
Aquestive Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-25,000$4.82$120k652,31726 d ago
Sep 8, 2026AQST
Aquestive Therapeutics, Inc.
XIn-the-money exercise
Common Stock
+91,743$0.96$88k677,31733 d ago
Sep 8, 2026AQST
Aquestive Therapeutics, Inc.
XIn-the-money exercise
Warrant (Right to Buy)derivative
-91,743$0.00$0033 d ago
Mar 7, 2025AQST
Aquestive Therapeutics, Inc.
AGrant or award
Common Stock
+272,000$0.00$01,098,478Mar 11, 2025
Mar 7, 2025AQST
Aquestive Therapeutics, Inc.
FTax withholding
Common Stock
-29,307$2.65$78k1,069,171Mar 11, 2025
Mar 9, 2025AQST
Aquestive Therapeutics, Inc.
FTax withholding
Common Stock
-53,998$2.65$143k1,015,173Mar 11, 2025
Mar 7, 2025AQST
Aquestive Therapeutics, Inc.
AGrant or award
Non-Qualified Stock Option (right to buy)derivative
+408,000$0.00$0408,000Mar 11, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Daniel Barber: insider trades and track record | InsiderTell